Transplant medicine faces a trade-off that has lasted for decades. To save a foreign organ from being attacked by the recipient's immune system, that very immune system must be weakened, at least in part. Anti-rejection drugs have made millions of additional life-years possible, but they carry risks and often need to be taken for life. German biotech Allogenetics wants to try intervening from the other side of the equation: modifying the organ before it enters the body.
The Hannover-based company has raised €3.8 million in a Pre-Series A round led by NBank Capital, with CARMA FUND, Life Science Valley Wachstumsfonds, and other investors. The capital will fund the studies required to advance the ALG-115 program toward a first-in-human trial in lung transplantation, planned for late 2027 or early 2028.
Treating the donor without treating the donor
The concept leverages a unique window in transplant medicine. After retrieval, certain organs can be maintained and perfused outside the body prior to implantation. This creates an opportunity to administer a therapy directly to the graft, avoiding—at least in theory—exposing the patient’s entire body to the treatment.
Allogenetics is developing an ex vivo gene therapy designed to downregulate molecules involved in antigen presentation, making the organ less recognizable as foreign to the recipient’s immune system.
The target is immune recognition
Rejection occurs because the immune system identifies molecular differences between donor and recipient cells. Targeting MHC class I and II molecules represents an attempt to dampen one of the key signals triggering this response.
It is a delicate strategy: making tissue less visible must not mean stripping it of normal biological functions or introducing new risks. For this reason, preclinical findings mark only the beginning of a process that must demonstrate both safety and clinical benefit in humans.
Why start with the lung
Lung transplantation is particularly complex, and chronic rejection remains one of the primary hurdles to long-term survival. Furthermore, ex vivo lung perfusion techniques provide a natural platform for treating the organ prior to implantation.
If the concept proves successful, the company envisions an approach that could potentially be applied to other organs as well. However, talking about eliminating immunosuppression today would be premature: ALG-115 has yet to undergo IND-enabling studies, and no human clinical data currently exists.
Gene therapy changes its address
We typically think of gene therapy as a treatment administered directly to a patient. Here, the immediate recipient is instead the organ. It is an intriguing conceptual shift because it allows the intervention to be localized and controlled during a window when the tissue is accessible outside the body.
This same logic could pave the way for a broader category of organ engineering: moving beyond merely preserving organs during transport to biologically enhancing or conditioning them for the recipient.
A modest round for a massive bet
€3.8 million is a modest sum compared to the funding typical of clinical-stage biotech majors. At this stage, however, the capital is not meant to commercialize a therapy; it is meant to clear a specific scientific hurdle. If regulatory preclinical studies prove compelling and the program advances into humans, the financial requirements will change entirely.
This is the characteristic rhythm of deep biotech: each round buys the opportunity to answer the next question. In the case of Allogenetics, that question is especially critical: Can we make a transplanted organ more tolerable without weakening the patient's entire immune system for years? The answer is still a long way off, but it is well worth pursuing.
